Hemiparesis, Spinal Cord Injury, Stroke, Traumatic Brain Injury, Upper-limb Motor Impairment
Conditions
Keywords
randomized, ssmd, neuromotor rehabilitation
Brief summary
This is a multicenter, randomized, controlled clinical study evaluating the safety and effectiveness of the Spatial StimelMD (SSMD) device for upper-limb neuromotor rehabilitation in adults with impairment following stroke or traumatic brain injury (TBI). Participants will be randomized to receive either SSMD therapy plus standard rehabilitation care or standard functional electrical stimulation (FES) plus standard care. Subjects will complete approximately 25 supervised treatment sessions over 5-6 weeks, with assessments at baseline, mid-treatment, post-treatment (primary endpoint), and a 1-month follow-up. The primary effectiveness endpoint is improvement in upper-limb motor function measured by the Fugl-Meyer Upper Extremity (FMA-UE) assessment. Secondary outcomes include movement metrics, EMG signal strength, functional independence, usability measures, and adverse event monitoring. The study plans to enroll approximately 150 subjects to achieve 126 completers, across 2-6 clinical sites.
Detailed description
CP-SSMD-01 is a multicenter, randomized, controlled clinical study designed to evaluate the safety and effectiveness of the Spatial StimelMD (SSMD) device for upper-limb neuromotor rehabilitation in adults with impairment following stroke or traumatic brain injury (TBI). The study compares SSMD therapy plus standard rehabilitation care to standard functional electrical stimulation (FES) plus standard care. Participants will complete approximately 25 supervised treatment sessions over a 5-6 week period. Subjects will undergo evaluations at baseline, mid-treatment, post-treatment (the primary endpoint), and a follow-up visit approximately one month after completing therapy. The primary outcome measure is improvement in upper-limb motor function assessed using the Fugl-Meyer Assessment for the Upper Extremity (FMA-UE). Secondary outcomes include additional measures of motor performance and movement quality, EMG-based muscle activation metrics, functional independence outcomes, usability assessments, and safety monitoring through adverse event reporting. The study aims to enroll approximately 150 participants, with an expected 126 completing the full protocol, across 2-6 clinical sites. This trial is intended to generate clinical evidence on whether SSMD therapy can support meaningful upper-limb motor recovery compared with a standard stimulation-based rehabilitation approach in individuals affected by stroke or TBI.
Interventions
DEVICESpatial StimelMD (SSMD)
Spatial StimelMD (SSMD) is a device-based neuromotor rehabilitation intervention used for upper-limb therapy. Participants receive SSMD therapy in supervised sessions as part of a structured rehabilitation program over approximately 5-6 weeks (about 25 sessions).
Functional electrical stimulation (FES) is a standard device-based intervention used in rehabilitation to stimulate muscle activation for upper-limb therapy. Participants receive FES in supervised sessions as part of standard rehabilitation care over approximately 5-6 weeks (about 25 sessions).
Sponsors
Motion Informatics LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
Not applicable. This is an open-label study with no masking.
Intervention model description
Participants are randomized into two parallel groups to receive either SSMD therapy plus standard rehabilitation care or standard functional electrical stimulation (FES) plus standard care over approximately 5-6 weeks.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults aged 18-80 years. 2. Clinically confirmed diagnosis of stroke or TBI within the past 12 months. 3. Presence of moderate to severe neuromotor impairment in at least one limb, as evidenced by medical evaluation and a score \<35 on the Fugl-Meyer Upper Extremity motor subscale (FMA-UE). 4. Capacity and willingness to provide informed consent, indicating understanding of the study purpose, procedures, and potential risks and benefits. 5. Subject is able to adhere to the study schedule and cognitively capable to perform the treatment. 6. Stable medical condition without ongoing acute complications that could interfere with participation.
Exclusion criteria
1. Presence of contraindications to electrical stimulation (ES), including implanted electronic medical devices (e.g., pacemakers, insulin pumps) or conditions that may be exacerbated by electrical stimulation (e.g., uncontrolled epilepsy). 2. Individuals with medical conditions, which are prone to seizures or motion sensitivity, at the investigator's discretion. 3. Individuals with light sensitivity, as the AR component may involve visual stimuli that could cause discomfort or adverse reactions in these patients. 4. Individuals with acute physical conditions or injuries that could interfere with the proper placement of the electrodes or safe use of the device. 5. Presence of spinal shock or unresolved acute spinal cord dysfunction, characterized by complete loss of reflexes, flaccid paralysis, or autonomic instability. 6. Current participation in other clinical trials that could confound the study results. 7. Severe cognitive impairment that precludes the ability to provide informed consent or reliably adhere to the study protocol, as determined by cognitive screening and clinical judgment. 8. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fugl-Meyer Assessment - Upper Extremity (FMA-UE) | Baseline to end of treatment (post-treatment; approximately 5-6 weeks) | Change from baseline to end of treatment in the Fugl-Meyer Assessment Upper Extremity (FMA-UE) motor function score (range 0-66), with higher scores indicating better motor function (better outcome). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Movement Quality (SSMD Assessment Mode) | Baseline to end of treatment (approximately 5-6 weeks) | Change in upper-limb movement quality measured using SSMD assessment mode metrics. |
| EMG Signal Strength (Threshold) | Baseline to end of treatment (approximately 5-6 weeks) | Change in EMG signal strength (threshold) measured during study assessments. |
| Functional Independence Measure (FIM) | Baseline to end of treatment (approximately 5-6 weeks) | Change from baseline to end of treatment in the Functional Independence Measure (FIM) total score (range 18-126), with higher scores indicating greater functional independence (better outcome). |
Countries
Israel
Contacts
CONTACTVictoria Lashinker
CONTACTJulia Sterlin
PRINCIPAL_INVESTIGATORDr.Boris Chelibian
Bnai Zion Medical Center
Outcome results
None listed